Could Aevi Genomic Medicine, Inc. (GNMX) Change Direction After Achieving 52-Week Low?

July 13, 2018 - By Richard Doty

The stock of Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) hit a new 52-week low and has $0.90 target or 6.00 % below today’s $0.96 share price. The 7 months bearish chart indicates high risk for the $56.96M company. The 1-year low was reported on Jul, 13 by If the $0.90 price target is reached, the company will be worth $3.42M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 3.99% or $0.04 during the last trading session, reaching $0.96. About 43,764 shares traded. Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) has risen 37.50% since July 13, 2017 and is uptrending. It has outperformed by 24.93% the S&P500.

Analysts await Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) to report earnings on August, 8. They expect $-0.15 earnings per share, up 31.82 % or $0.07 from last year’s $-0.22 per share. After $-0.15 actual earnings per share reported by Aevi Genomic Medicine, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company has market cap of $56.96 million. The Company’s lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn's disease. It currently has negative earnings. The firm was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.